Agomab Gets $100m In Fifth Largest European Venture Round This Year
But the cash will probably not be enough to prove its lead compound’s efficacy for a severe form of Crohn’s disease.
You may also be interested in...
A second pivotal hit positions Sanofi and Regeneron’s antibody for approval in COPD – but other biologics are coming fast.
Novo Nordisk and Eli Lilly are duking it out in the market, but dozens of competitors are waiting in the wings.
The UK big pharma gets a first-in-class approval in breast cancer, but a challenger is emerging.